Skip to main content
. 2020 Jun 28;13(6):969–980. doi: 10.1093/ckj/sfaa049

Table 3.

Pathology and intravitreal VEGF blockade use

Reference n Age(s) (years) Gender Agent used Clinical pathology
Hanna et al. [11] 4 82, 54, 53 and 65 F Bev & Ran Case 1 de novo MCD (biopsy+), Cases 2–4 increased proteinuria, CKD progression, HTN worsening
Bagheri et al. [31] 18/40 60.3 ± 9.2 33 F and 7 M Bev Increased proteinuria in 18/40, 45% of patients
Cheungpasitporn et al. [44] 2 52, 67 2 M Bev Case 1, MGN and Case 2 TMA (biopsy+)
Diabetic Retinopathy Clinical Research Network [45] 3 NR NR Bev Decreased eGFR
Georgalas et al. [46] 2 51 and 68 F and M Ran & Bev Decreased eGFR, HD started
Jamrozy-Witkowska et al. [47] 1 NR NR NR Decreased eGFR
Kenworth et al. [48] 1 88 F Bev Increased proteinuria
Khneizer et al. [49] 1 74 M Bev MGN (biopsy+)
Morales et al. [50] 1 56 M Ran DN (biopsy+)
Nobakht et al. [51] 1 96 F Bev → Ran → Aflib cFSGS (biopsy+) + low systemic VEGF level
Pellé et al. [52] 1 77 F Ran TMA (biopsy+)
Perez-Valdivia et al. [53] 1 54 M Bev Relapsed MCD (biopsy+)
Sato et al. [54] 1 16 F Bev Relapsed MCD (biopsy+)
Hanna et al. [56] 1 38 F Bev → Ran Worsening HTN and proteinuria, lessened with Ran use versus Bev
Touzani et al. [57] 1 72 M Bev Endotheliosis/possible TMA (biopsy+)
Tran [58] 1 51 M Bev AIN (biopsy+)
Yen et al. [59] 1 56 M Bev TMA (biopsy+)
Hanna et al. [manuscript under review] 3 43, 56 and 77 M, F and F

  • Bev (Cases 1 and 2)

  • Aflib (Case 3)

  • Cases 1 and 2: DN and chronic TMA (biopsy+)

  • Case 3: FSGS with chronic TMA features (biopsy+)
CCS (Shye et al.) 3 46, 58 and 59 3 M

  • Case 1 Bev → Ran

  • Case 2 Bev

  • Case 3 Bev → Ran

  • All: increased proteinuria, CKD progression and HD

  • Case 1 Worsening proteinuria, CKD progression and HD

  • Case 2 DN + FSGS with collapsing features + AIN (biopsy+)

  • Case 3 DN + AIN þ low systemic VEGF level (biopsy+)

Biopsy only if (biopsy+) stated. Aflib, aflibercept; AIN, acute interstitial nephritis; Bev, bevacizumab; biopsy+, biopsy obtained; CCS, current case series; F, female; HTN, hypertension; M, male; MGN, membranous glomerulonephritis; n, number of patients; NR, not recorded; Ran, ranibizumab.